8-K: Seer Inc. Cuts 2026 Revenue Guidance, Q3 Results Mixed

Seer, Inc. announced third-quarter 2026 revenue of $4.0 million, a 3% decrease year-over-year, and significantly lowered its full-year revenue guidance due to extended sales cycles.

Summary

• Seer, Inc. reported third-quarter 2026 revenue of $4.0 million, a slight decrease from $4.1 million in the prior year's third quarter, but an increase from $3.1 million in the second quarter of 2026.
• The company ended the quarter with $198.1 million in cash, cash equivalents, and investments.
• Full-year 2026 revenue guidance has been revised downwards to a range of $13.5 million to $14.5 million, from the previous range of $16 million to $18 million.
• This downward revision is attributed to continued pressure on academic and government funding, leading to extended sales cycles.
• Operating expenses decreased by 23% year-over-year to $16.5 million in the third quarter of 2026, primarily due to lower employee compensation costs.
• Net loss for the third quarter of 2026 was $13.7 million, an improvement from $18.2 million in the prior-year period.
• For the nine months ended September 30, 2026, net cash used in operating activities was approximately $34.5 million, resulting in a free cash flow of approximately negative $34.8 million.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a negative sentiment due to the significant reduction in revenue guidance and continued net losses, despite some operational improvements and positive scientific developments.

Positives

• Revenue increased sequentially from $3.1 million in Q2 2026 to $4.0 million in Q3 2026.
• Operating expenses decreased by 23% year-over-year to $16.5 million, driven by reduced employee compensation.
• Net loss improved to $13.7 million in Q3 2026 from $18.2 million in Q3 2025.
• The company ended the quarter with a strong cash position of $198.1 million.
• Scientific highlights include an increase in publications and preprints using Proteograph to 116, and promising preliminary findings from the PRECISE-SG100K study.
• Established customers continued to purchase consumables, and new pharmaceutical customers adopted the platform.
• The company believes it has sufficient capital to reach cash flow breakeven based on its current operating plan.

Negatives

• Third-quarter revenue of $4.0 million decreased by 3% compared to the prior-year period ($4.1 million).
• Full-year 2026 revenue guidance was significantly reduced to $13.5 million $14.5 million from $16 million $18 million.
• The company continues to incur substantial net losses, with a Q3 2026 net loss of $13.7 million.
• Net cash used in operating activities for the first nine months of 2026 was $34.5 million, with free cash flow at negative $34.8 million.
• Extended sales cycles due to pressure on academic and government funding are impacting revenue realization.

Risks

• Continued pressure on academic and government funding may further extend sales cycles and impact future revenue.
• The company's ability to achieve cash flow breakeven depends on its current operating plan and execution.
• The ITC investigation outcome remains pending, although the investigative staff recommended favorable orders for Seer.
• The company's reliance on mass spectrometry and proteomic insights means its success is tied to the adoption and advancement of these technologies.

Future Outlook

Full-year 2026 revenue is now expected to be in the range of $13.5 million to $14.5 million, a reduction from the previous guidance of $16 million to $18 million. The company believes it has sufficient capital to reach cash flow breakeven under its current operating plan.

Management Comments

• "This quarter, our customers continued to demonstrate what Proteograph makes possible, from new discoveries in population-scale research to emerging applications in AI, while established customers returned to purchase consumables and new pharmaceutical customers adopted the platform," said Omid Farokhzad, Chair and Chief Executive Officer.
• "Proteograph fundamentally expands the biology researchers can see with mass spectrometry. Our focus is to translate that differentiated value into sustained revenue growth by expanding sample volume within customer accounts and building relationships that support repeat use."
• "With a strong balance sheet and growing evidence of the platforms value, I remain confident in Seers opportunity and committed to building long-term value for our shareholders."

Industry Context

StockSavvy.ai notes that Seer operates in the rapidly evolving field of proteomics, aiming to provide deeper and more comprehensive biological insights than traditional methods. The company's challenges in meeting revenue guidance, attributed to funding pressures and extended sales cycles, reflect broader economic conditions impacting research budgets, particularly in academic and government sectors. Competitors in the life sciences tools and diagnostics space often face similar hurdles related to R&D investment and market adoption.

Comparison to Industry Standards

• The reported Q3 revenue of $4.0 million represents a 3% year-over-year decrease, which is concerning in a sector that typically aims for consistent growth. For instance, companies like Thermo Fisher Scientific (TMO) or Agilent Technologies (A) often report mid-to-high single-digit or even double-digit revenue growth in their respective segments.
• The significant reduction in full-year revenue guidance from $16-18 million to $13.5-14.5 million indicates a substantial miss against prior expectations, a deviation from the norm for companies performing at or above industry benchmarks.
• While operating expenses decreased by 23%, the continued net loss of $13.7 million in Q3 and negative free cash flow of $34.8 million for the nine-month period highlight ongoing profitability challenges. Many established players in the life sciences industry, while also investing heavily in R&D, aim for positive or near-breakeven cash flow from operations at this stage of market penetration.
• The scientific advancements highlighted, such as the PRECISE-SG100K study and independent validation in Clinical Proteomics, are positive but need to translate more effectively into commercial success to align with industry growth expectations.

Legal Proceedings

• An ITC investigation brought by Seer and Brigham and Women's Hospital against Nanomics Biotechnology Co., Ltd. is ongoing. The ITC's investigative staff recommended granting the full exclusion and cease-and-desist orders requested. The Commission's final determination is pending and expected by year-end.

Related Party Transactions

• Related party revenue was $0.1 million in Q3 2026.

Stakeholder Impact

• Shareholders may be concerned by the reduced revenue guidance and continued net losses, potentially impacting stock valuation.
• Customers may see continued innovation and support, but extended sales cycles could affect their research timelines.
• Employees may face uncertainty due to the company's financial performance and the need for disciplined spending.

Next Steps

• Continue to focus on expanding sample volume within customer accounts and building relationships for repeat use.
• Monitor the outcome of the ITC investigation, with a final determination expected by year-end.
• Continue to invest in commercial adoption and product innovation while maintaining disciplined spending.
• Work towards achieving cash flow breakeven.

Key Dates

Recommendation

The company shows promising scientific advancements and a strong cash position, but the significant reduction in revenue guidance and continued losses warrant caution. The ongoing ITC investigation adds another layer of uncertainty. A 'hold' recommendation reflects a balanced view of potential upside from technology adoption against the current financial performance and market headwinds.

Keywords

proteomics, Proteograph, mass spectrometry, revenue guidance, financial results, biotechnology, pharmaceutical, research